A gain-of-function mutation in PIK3CA was linked to acquired resistance to FGFR2 inhibitors in a patient with intrahepatic cholangiocarcinoma, underscoring its role in disease progression and therapy resistance [66]. Here, FGFR2 is linked to cholangiocarcinoma.